• Je něco špatně v tomto záznamu ?

Biomarkers of Inflammation and Progression During Immunotherapy in Patients With Metastatic Renal Cell Carcinoma

M. Spisarova, B. Melichar, J. Juranova, A. Zemankova, T. Adam, K. Matousova, L. Javorska, LK. Krcmova, D. Turonova, H. Studentova

. 2023 ; 37 (1) : 393-399. [pub] -

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004715

BACKGROUND/AIM: Biomarkers that would identify patients unlikely to respond to immunotherapy with immune checkpoint inhibitors (ICIs) remain an unmet medical need. PATIENTS AND METHODS: In the present study, we have retrospectively evaluated the association between biomarkers of immune activation and outcome in metastatic renal cell carcinoma (mRCC) patients treated with ICIs. The laboratory and clinical data of 79 consecutive patients with histologically confirmed mRCC treated with ICI-based immunotherapy have been analyzed. RESULTS: Patients who progressed or died at 4 months had higher prognostic score, higher serum C-reactive protein (CRP) and neopterin, and urinary neopterin, and lower serum albumin and hemoglobin concentration. CONCLUSION: Biomarkers of activation of immune response, in particular serum neopterin/creatinine ratio, are associated with outcome in mRCC patients treated with ICI immunotherapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004715
003      
CZ-PrNML
005      
20230425171656.0
007      
ta
008      
230418s2023 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/invivo.13091 $2 doi
035    __
$a (PubMed)36593038
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Spisarova, Martina $u Department of Oncology, Palacký University, Faculty of Medicine and Dentistry, and University Hospital, Olomouc, Czech Republic
245    10
$a Biomarkers of Inflammation and Progression During Immunotherapy in Patients With Metastatic Renal Cell Carcinoma / $c M. Spisarova, B. Melichar, J. Juranova, A. Zemankova, T. Adam, K. Matousova, L. Javorska, LK. Krcmova, D. Turonova, H. Studentova
520    9_
$a BACKGROUND/AIM: Biomarkers that would identify patients unlikely to respond to immunotherapy with immune checkpoint inhibitors (ICIs) remain an unmet medical need. PATIENTS AND METHODS: In the present study, we have retrospectively evaluated the association between biomarkers of immune activation and outcome in metastatic renal cell carcinoma (mRCC) patients treated with ICIs. The laboratory and clinical data of 79 consecutive patients with histologically confirmed mRCC treated with ICI-based immunotherapy have been analyzed. RESULTS: Patients who progressed or died at 4 months had higher prognostic score, higher serum C-reactive protein (CRP) and neopterin, and urinary neopterin, and lower serum albumin and hemoglobin concentration. CONCLUSION: Biomarkers of activation of immune response, in particular serum neopterin/creatinine ratio, are associated with outcome in mRCC patients treated with ICI immunotherapy.
650    _2
$a lidé $7 D006801
650    12
$a karcinom z renálních buněk $x farmakoterapie $7 D002292
650    12
$a nádory ledvin $x farmakoterapie $7 D007680
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a neopterin $x terapeutické užití $7 D019798
650    _2
$a biologické markery $7 D015415
650    _2
$a zánět $7 D007249
650    _2
$a imunoterapie $7 D007167
655    _2
$a časopisecké články $7 D016428
700    1_
$a Melichar, Bohuslav $u Department of Oncology, Palacký University, Faculty of Medicine and Dentistry, and University Hospital, Olomouc, Czech Republic
700    1_
$a Juranova, Jarmila $u Department of Hematologic Oncology, Palacký University, Faculty of Medicine and Dentistry, and University Hospital, Olomouc, Czech Republic
700    1_
$a Zemankova, Anezka $u Department of Oncology, Palacký University, Faculty of Medicine and Dentistry, and University Hospital, Olomouc, Czech Republic
700    1_
$a Adam, Tomas $u Department of Clinical Biochemistry, Palacký University, Faculty of Medicine and Dentistry, and University Hospital, Olomouc, Czech Republic
700    1_
$a Matousova, Katerina $u Department of Clinical Biochemistry and Diagnostics, University Hospital, Hradec Králové, Czech Republic
700    1_
$a Javorska, Lenka $u Department of Clinical Biochemistry and Diagnostics, University Hospital, Hradec Králové, Czech Republic
700    1_
$a Krcmova, Lenka Kujovska $u Department of Clinical Biochemistry and Diagnostics, University Hospital, Hradec Králové, Czech Republic $u Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
700    1_
$a Turonova, Dorota $u Department of Clinical Biochemistry and Diagnostics, University Hospital, Hradec Králové, Czech Republic $u Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
700    1_
$a Studentova, Hana $u Department of Oncology, Palacký University, Faculty of Medicine and Dentistry, and University Hospital, Olomouc, Czech Republic; hana.studentova@fnol.cz
773    0_
$w MED00175831 $t In vivo (Athens, Greece) $x 1791-7549 $g Roč. 37, č. 1 (2023), s. 393-399
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36593038 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425171653 $b ABA008
999    __
$a ok $b bmc $g 1925040 $s 1190924
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 37 $c 1 $d 393-399 $e - $i 1791-7549 $m In Vivo $n In Vivo $x MED00175831
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace